Literature DB >> 23040748

Management options for persistent postoperative acromegaly.

Nestoras Mathioudakis1, Roberto Salvatori.   

Abstract

This article presents management options for the patient with acromegaly after noncurative surgery. The current evidence for repeat surgery, adjuvant medical therapy with somatostatin analogues, dopamine agonists, the growth hormone receptor antagonist pegvisomant, combination medical therapy, and radiotherapy in the context of persistent postoperative disease are summarized. The relative advantages and disadvantages of each of these treatment modalities are explored, and a general treatment algorithm that integrates these modalities is proposed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040748      PMCID: PMC6031123          DOI: 10.1016/j.nec.2012.06.005

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  101 in total

1.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

Authors:  P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

2.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

3.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

4.  Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Authors:  J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-11-17       Impact factor: 2.949

5.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.

Authors:  Annamaria Colao; Rosario Pivonello; Renata S Auriemma; Mariano Galdiero; Silvia Savastano; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2007-11       Impact factor: 6.664

6.  Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Authors:  Raquel S Jallad; Nina R C Musolino; Luiz R Salgado; Marcello D Bronstein
Journal:  Clin Endocrinol (Oxf)       Date:  2005-08       Impact factor: 3.478

7.  Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Authors:  M Sherlock; E Fernandez-Rodriguez; A Aragon Alonso; R C Reulen; J Ayuk; R N Clayton; G Holder; M C Sheppard; A Bates; P M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2009-01-21       Impact factor: 5.958

8.  Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study.

Authors:  R S Auriemma; R Pivonello; M Galdiero; M C De Martino; M De Leo; G Vitale; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

9.  One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.

Authors:  Ph Caron; M Bex; D R Cullen; U Feldt-Rasmussen; A M Pico Alfonso; S Pynka; K Racz; J Schopohl; A Tabarin; M J Valimaki
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

10.  Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Authors:  T Lucas; R Astorga
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

View more
  3 in total

Review 1.  Octreotide-Resistant Acromegaly: Challenges and Solutions.

Authors:  Giuliana Corica; Marco Ceraudo; Claudia Campana; Federica Nista; Francesco Cocchiara; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Diego Ferone; Federico Gatto
Journal:  Ther Clin Risk Manag       Date:  2020-05-05       Impact factor: 2.423

2.  Approach to the Patient With Treatment-resistant Acromegaly.

Authors:  Eva C Coopmans; Aart J van der Lely; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 3.  Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms.

Authors:  Michael A Mooney; Elias D Simon; Andrew S Little
Journal:  Front Surg       Date:  2016-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.